Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$69.28 USD

69.28
1,720,426

-3.75 (-5.13%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $69.29 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Value Investors Buy Henry Schein (HSIC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Henry Schein (HSIC) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

HSIC vs. MMSI: Which Stock Is the Better Value Option?

by Zacks Equity Research

HSIC vs. MMSI: Which Stock Is the Better Value Option?

Indrajit Bandyopadhyay headshot

4 Stocks to Buy From the Prospering Dental Supplies Industry

by Indrajit Bandyopadhyay

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), backed by the strength of the dental business and acquisitions.

Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Henry Schein (HSIC) Gains From Strong Global Network Amid FX Woes

by Zacks Equity Research

Henry Schein's (HSIC) dental software business is progressing well despite a challenging business environment.

Here's Why Henry Schein (HSIC) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Henry Schein (HSIC) Down 1.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.

Here's Why Henry Schein (HSIC) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips

by Zacks Equity Research

Henry Schein's (HSIC) second quarter 2023 performance demonstrates strength in the North American dental business.

Compared to Estimates, Henry Schein (HSIC) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Henry Schein (HSIC) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 4.80% and 0.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 MedTech Stocks Likely to Top Estimates This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

Staar Surgical (STAA) Q2 Earnings Beat Estimates

by Zacks Equity Research

Staar Surgical (STAA) delivered earnings and revenue surprises of 25% and 0.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will High Medical Costs Hurt Cigna (CI) in Q2 Earnings?

by Zacks Equity Research

Cigna's (CI) Q2 results are likely to reflect strength in the specialty pharmacy business and growing medical customer base, partly offset by higher medical expenses.

Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.

Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 5.06% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

What's in the Cards for Universal Health (UHS) in Q2 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.

Henry Schein (HSIC) Stock Moves -0.78%: What You Should Know

by Zacks Equity Research

Henry Schein (HSIC) closed at $78.81 in the latest trading session, marking a -0.78% move from the prior day.

Henry Schein (HSIC) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Henry Schein (HSIC) closed at $81.10, marking a +0.25% move from the previous day.